title: [Analysis of the duration of and reasons for changing the first combination of antiretroviral therapy].
abstract: OBJECTIVE
  To determine the duration of and reasons behind changing the various combinations of drugs used for the initiation of antiretroviral treatment in naïve patients.
  
  
  METHODS
  A retrospective observational study that included all patients with HIV infection who started antiretroviral therapy in a high-tech university reference hospital during the period from 1 January 2003 and 31 December 2005. Patients were followed until 31 December 2008. To estimate the cumulative probability of discontinuation the Kaplan-Meier method was used.
  
  
  RESULTS
  A total of 441 patients were included. The average duration of the first treatment was 384 (interquartile interval 84-1290) days. The regimen based on non-nucleoside reverse transcriptase inhibitors and those that included as nucleosides abacavir or tenofovir in combination with lamivudine or emtricitabine showed a significantly longer duration than the rest. The main reasons for termination were the side effects, although in a lesser percentage than that obtained in previous studies. No associations were found between the rest of the characteristics of the patients or of the treatment and the risk of termination.
  
  
  CONCLUSIONS
  Although the duration of the first antiretroviral treatment remains short, currently fewer changes are made due to side effects and due to loss to follow-up. The reasons may be better tolerance and less complexity. However, more studies are needed to determine the benefits of one regimen or another, and to be able to generalise the results.
authors.affiliation: Servicio de Farmacia, Hospital Clínic Barcelona, Barcelona, España. mmartin@clinic.ub.es
authors.forename: M T
authors.initials: MT
authors.lastname: Martín
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: M
authors.initials: M
authors.lastname: Massanes
authors.forename: E
authors.initials: E
authors.lastname: del Cacho
authors.forename: E
authors.initials: E
authors.lastname: Carcelero
authors.forename: M
authors.initials: M
authors.lastname: Tuset
authors.forename: C
authors.initials: C
authors.lastname: Codina
authors.forename: J M
authors.initials: JM
authors.lastname: Miro
authors.forename: J M
authors.initials: JM
authors.lastname: Gatell
authors.forename: J
authors.initials: J
authors.lastname: Ribas
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D044966:Anti-Retroviral Agents